CD274 and small cell lung carcinoma: Since there were no PD-1/PD-L1 inhibitors for SCLC available in China at the point of approval of our study protocol (14 August 2019), the standard-of-care of EC chemotherapy, and not immunochemotherapy, was adopted as the control arm in ETER701.